C07K 2319/034
Containing a motif for targeting to the periplasmic space of gram negative
Official title: containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
C07K2319/034 (Containing a motif for targeting to the periplasmic space of gram negative) appears on 116 US grants and 99 published applications in this corpus.
Search patents in C07K- Granted patents
- 116
- Published applications
- 99
- Assignees
- 83
- Inventors
- 254
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 2 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 3 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 4 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 6 | 0 |
| 1995 | 4 | 0 |
| 1996 | 5 | 0 |
| 1997 | 6 | 0 |
| 1998 | 7 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 1 |
| 2002 | 2 | 2 |
| 2003 | 5 | 5 |
| 2004 | 2 | 2 |
| 2005 | 1 | 5 |
| 2006 | 2 | 4 |
| 2007 | 1 | 2 |
| 2008 | 4 | 6 |
| 2009 | 0 | 3 |
| 2010 | 2 | 2 |
| 2011 | 3 | 10 |
| 2012 | 0 | 3 |
| 2013 | 1 | 2 |
| 2014 | 6 | 3 |
| 2015 | 4 | 7 |
| 2016 | 7 | 2 |
| 2017 | 4 | 5 |
| 2018 | 2 | 4 |
| 2019 | 3 | 5 |
| 2020 | 2 | 5 |
| 2021 | 5 | 3 |
| 2022 | 2 | 4 |
| 2023 | 1 | 6 |
| 2024 | 4 | 3 |
| 2025 | 2 | 2 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same5 May 2026US 12,617,815 B2Amunix Pharmaceuticals, Inc.
- E. coli deficient in Lon and SulA for gene targeting13 May 2025US 12,297,239 B2National Research Council of Canada
- CRM197 protein expression25 Feb 2025US 12,234,266 B2Obi Pharma, Inc.
- Protein complex including botulinum toxin translocation domain and endolysin and antibacterial composition including same24 Dec 2024US 12,171,814 B2Mvrix Co., Ltd.
- Myeloid differentiation factor 2 (MD2) signaling and modulation6 Aug 2024US 12,054,517 B2The Regents of the University of California
- Barcoded xten polypeptides and compositions thereof, and methods for making and using the same30 Jul 2026US 2026/0217758 A1Amunix Pharmaceuticals, Inc.
- Methods for expression of fusion-free bovine ultralong cdr3 scaffold16 Jul 2026US 2026/0201020 A1Pelican Technology Holdings, Inc.
- Recombinant Protein22 Jan 2026US 2026/0022387 A1Cytiva BioProcess R&D AB
- E. coli for the production of diphtheria toxin polypeptides4 Dec 2025US 2025/0368692 A1National Research Council of Canada
- Methods and compositions for multivalent vaccines15 May 2025US 2025/0152694 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Expression of functional antibody fragments507US 5,648,237 AGenentech, Inc. · 1997
- Modular assembly of antibody genes, antibodies prepared thereby and use298US 5,618,920 AXoma Corporation · 1997
- Modular assembly of antibody genes, antibodies prepared thereby and use250US 6,204,023 B1Xoma Corporation · 2001
- Modular assembly of antibody genes, antibodies prepared thereby and use136US 5,693,493 AXoma Corporation · 1997
- Modular assembly of antibody genes, antibodies prepared thereby and use127US 5,698,417 AXoma Corporation · 1997